Ahmed Mousa
Director Ejecutivo en VICORE PHARMA HOLDING AB .
Fortuna: - $ al 31/05/2024
Origen de la red de primer grado Ahmed Mousa.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Biotechnology | 24 | |
| Public Company | Pharmaceuticals: Major | 16 | |
Covington & Burling LLP
 Covington & Burling LLP Miscellaneous Commercial ServicesCommercial Services Covington & Burling LLP provides legal services. It also provides support services in the following administrative departments including accounting, human resources, information research services, information technology services, library, operations, marketing, practice systems support, recruitment, attorney and alumni relations, and professional development. The company was founded by J. Harry Covington and Edward B. Burling on January 1, 1919 and is headquartered in Washington, DC.
4
| Private Company | Miscellaneous Commercial Services | 4 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a Ahmed Mousa a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| JUNIPER PHARMACEUTICALS INC | Pharmaceuticals: Major | Chairman Comptroller/Controller/Auditor | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| HALOZYME THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
| TRANSGENE | Biotechnology | Director/Board Member Director/Board Member | |
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Investment Managers | Private Equity Investor | |
| SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal Chief Operating Officer | |
| CELATOR PHARMACEUTICALS INC | Pharmaceuticals: Major | Director/Board Member | |
Aerpio Therapeutics, Inc.
 Aerpio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Aerpio Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases. The firm develops small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Its two lead programs include a tie-2 activator for diabetic macular edema and vascular leak, and a hypoxia-inducible factor 1-a stabilizer for wound healing and the treatment of inflammatory bowel disease. The company was founded by Joseph H. Gardner and Robert Shalwitz in 2011 and is headquartered in Cincinnati, OH. | Pharmaceuticals: Major | Chairman Director/Board Member | |
HealthCap AB
 HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor Private Equity Investor | |
| MORPHOSYS AG | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| GLENMARK PHARMACEUTICALS LIMITED | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
| Karolinska Institutet | College/University | Doctorate Degree Doctorate Degree Doctorate Degree Doctorate Degree | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree Doctorate Degree | |
| University of Toronto | College/University | Undergraduate Degree Doctorate Degree | |
| University of Massachusetts | College/University | Undergraduate Degree Corporate Officer/Principal | |
| University of Uppsala | College/University | Corporate Officer/Principal Graduate Degree Graduate Degree | |
Vicore Pharma AB
 Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
Boehringer Ingelheim Corp.
 Boehringer Ingelheim Corp. Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim Corp. develops, manufactures and markets health care products. It focuses in the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. The company was founded on December 8, 1986 and is headquartered in Ridgefield, CT. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| University of Lund | College/University | Graduate Degree Doctorate Degree Undergraduate Degree | |
| University of Utrecht | College/University | Doctorate Degree | |
| University of Nice Sophia Antipolis | College/University | Doctorate Degree | |
| University of Gothenburg | College/University | Doctorate Degree Doctorate Degree | |
| BONESUPPORT HOLDING AB | Medical Specialties | Corporate Officer/Principal | |
Genzyme Europe BV
 Genzyme Europe BV Pharmaceuticals: MajorHealth Technology Part of Sanofi, Genzyme Europe BV is a Dutch company that develops and manufactures pharmaceutical and biotherapeutic products. The company is based in Amsterdam, Netherlands. | Pharmaceuticals: Major | President Sales & Marketing | |
| Organon International BV | President | ||
| HANSA BIOPHARMA AB | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
| Harvard Medical School | College/University | Corporate Officer/Principal Doctorate Degree | |
| SWEDISH ORPHAN BIOVITRUM AB | Pharmaceuticals: Major | Director/Board Member | |
| WILSON THERAPEUTICS AB | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| PHARVARIS N.V. | Pharmaceuticals: Major | Founder Director/Board Member | |
| Y-MABS THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Microbiotica Ltd.
 Microbiotica Ltd. BiotechnologyHealth Technology Microbiotica Ltd. performs research and experimental development on biotechnology. The company was founded by Michael Anthony Romanos, Trevor David Lawley and Gordon Dougan in December 2016 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chairman | |
Healthcap Annex Fund I-Ii Bis Gp AB
 Healthcap Annex Fund I-Ii Bis Gp AB Financial ConglomeratesFinance Healthcap Annex Fund I-Ii Bis Gp AB operates as an investment holding Swedish company. The private company is based in Stockholm, Sweden. | Financial Conglomerates | Director/Board Member | |
INIM Pharma AB
 INIM Pharma AB Pharmaceuticals: MajorHealth Technology INIM Pharma AB operates as drug development company that focuses on the development of immunomodulatory drugs for interstitial lung diseases. It develops a new local treatment for severe rare lung diseases such as idiopathic pulmonary fibrosis. The company was founded by Carl-Johan Dalsgaard and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Executive Officer Chairman Director/Board Member Director/Board Member | |
| EllAug AB | Director/Board Member | ||
| GALECTO, INC. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | Biotechnology | Director/Board Member | |
Pharvaris GmbH
 Pharvaris GmbH Pharmaceuticals: MajorHealth Technology Pharvaris GmbH operates as a clinical-stage company. It specializes in medicinal chemistry, drug discovery and development and hereditary angioedema. The company was founded by Berndt A. E. Modig, Jochen Knolle, Anne Lesage and Hans G. C. P. Schikan in October 2015 and is headquartered in Zug, Switzerland. | Pharmaceuticals: Major | Founder | |
Synox Therapeutics Ltd.
 Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
Tribune Therapeutics AB
 Tribune Therapeutics AB Miscellaneous Commercial ServicesCommercial Services Tribune Therapeutics AB is a preclinical biopharmaceutical company that focuses on developing novel medicines to treat patients with fibrotic diseases. Healthcap and Novo Seeds provided funding for the company, and they are based in Stockholm, Sweden. The Swedish company was created by Healthcap and Novo Seeds, the early-stage investment and company creation team of Novo Holdings. The company was founded in 2020 and has in-licensed an asset from one of the largest technology transfer offices in the Nordic region. The founders of the company are Håvard Attramadal, Ole J. Kaasbøll, and Georg Vo Beiske, who has been the CEO since 2020. | Miscellaneous Commercial Services | Director/Board Member | |
| Mips Helmet AB | Director/Board Member | ||
Disruptive Pharma AB
 Disruptive Pharma AB Pharmaceuticals: MajorHealth Technology Disruptive Pharma AB is a pharmaceutical company based in Uppsala, Sweden, with a passion for innovation in drug products. The Swedish company has perfected the groundbreaking mesoporous magnesium carbonate (mmc) drug delivery technology, which makes it easier to develop amorphous drug candidates. By combining the mmc formulation technology with drug compounds, they can enhance existing products or assist in formulating new therapies. Disruptive Pharma seeks commercial partnership or licensing to industry partners within the drug improvement business area. The company was founded in 2018 by Maria Strömme, and the CEO is Peter Åsberg. | Pharmaceuticals: Major | Director/Board Member | |
| Aurelia Invest AB | Director/Board Member |
Estadísticas
Internacional
| Suecia | 18 |
| Estados Unidos | 13 |
| Suiza | 6 |
| Países Bajos | 6 |
| Francia | 4 |
Sectorial
| Health Technology | 32 |
| Consumer Services | 10 |
| Finance | 5 |
| Technology Services | 2 |
| Commercial Services | 2 |
Operativa
| Director/Board Member | 187 |
| Corporate Officer/Principal | 87 |
| Independent Dir/Board Member | 63 |
| Chief Tech/Sci/R&D Officer | 35 |
| Director of Finance/CFO | 30 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Jacob Uno Stanley Gunterberg | 33 |
| Peter Kiener | 25 |
| James Geraghty | 25 |
| Jean Bizzari | 24 |
| Darlene Deptula-Hicks | 24 |
| Julian Adams | 23 |
| Johannes G. C. P. Schikan | 22 |
| Carl-Johan Dalsgaard | 21 |
| Matthew Sherman | 16 |
| Steven Prelack | 15 |
| Allan Reine | 14 |
| Bertil Lindmark | 14 |
| Donald C. Ross | 13 |
| Margareta Elisabeth Björk | 12 |
- Bolsa de valores
- Insiders
- Ahmed Mousa
- Conexiones Empresas
